Should You Buy PAVmed Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, PAVmed Inc. (PAVM) scores 4.6/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $3.92, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 1 of 6 CirclFi valuation models project upside for PAVmed Inc. (PAVM) at $3.92 — the model consensus leans bearish, with a Quality Score of 4.6/10 and Value-Trap risk of 58/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for PAVmed Inc. (PAVM) in 2026?
What Is the Bull Case vs the Bear Case for PAVmed Inc. (PAVM)?
| Bull case — $4.30 target (+9.8%) | Bear case — $0.19 target (-95.2%) |
|---|---|
| Industry tailwind: regulatory pathway clarity could provide meaningful support for PAVmed Inc.'s revenue and margin trajectory in the Medical Devices space. | According to the CirclFi Quality of Company (QOC) framework, PAVmed Inc.'s score of 4.6/10 signals fundamental weaknesses that could undermine the investment thesis. |
| According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. | |
| According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.19 (-95.2%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +105.1% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. | |
| Industry headwind: clinical trial failure represents a meaningful risk for PAVmed Inc. and its Medical Devices peers. |
How Does PAVM Compare to Its Medical Devices Peers?
Valuation data pages: AEMD · RBOT · RMSL · CSDX · ALUR · HSCS · ESMC · CTKB · BTCY · IRMD · PODD
Which Other Stocks Score Like PAVM on Quality?
Closest companies to PAVM’s Quality of Company score of 4.6/10, across all industries.
- RAPH — Raphael Pharmaceutical Inc. (QOC 4.6) · analysis
- VERA — Vera Therapeutics, Inc. (QOC 4.6) · analysis
- BSAI — BluSky AI, Inc. (QOC 4.6) · analysis
- SION — Sionna Therapeutics, Inc. (QOC 4.6) · analysis
- IPXG — Inflection Point Acquisition Corp. VII (QOC 4.6) · analysis
- BLNC — Balance Labs, Inc. (QOC 4.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does PAVM Appear In?
So Is PAVmed Inc. (PAVM) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on PAVmed Inc. at $3.92. 5/6 models flag overvaluation, median fair value sits at $1.11 (-71.7%), and the risk-reward profile appears unfavorable. Quality at 4.6/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. PAVmed Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PAVM Stock?
Should I buy PAVM stock right now?
Based on CirclFi's multi-model analysis, 1 of 6 models see upside for PAVM at $3.92. The models are divided, which means the investment case depends heavily on your assumptions about PAVmed Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in PAVmed Inc.?
Key risks include: an elevated Value Trap score of 58/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.6/10, indicating fundamental weakness; limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (2204% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does PAVM compare to its competitors?
Among Medical Devices peers, PAVM holds a Quality Score of 4.6/10. Comparable companies include AEMD (QOC 4.6), RBOT (QOC 4.6), RMSL (QOC 4.6). The relative ranking helps investors identify whether PAVM offers better fundamental quality than alternatives in the same sector.
Is PAVM a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PAVM's Quality Score of 4.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy PAVM at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $0.19 to $4.30. At $3.92, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PAVM.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad